Key Publications

Key Publications

Distinct CXCR3 ligands differentially activate STAT-dependent CD4+ T-cell polarization and regulate experimental autoimmune encephalomyelitis.

2012 Zohar, Y., Barsheshet, Y., Netze, N., Wildbaum, G. & Karin, N. (Submitted) (2012)
The manuscript defines a novel chemokine that regulates the biological functions of FOXp3- CD4+ of inflammatory.

Dissecting the Autocrine and Paracrine Roles of the CCR2-CCL2 Axis in Tumor Survival and Angiogenesis.

2012 Izhak, L., Wildbaum, G., Jung, S., Stein, A., Shaked, Y. & Karin, N. PloS one 7, e28305 (2012).
This manuscript visualizes how bone marrow derived macrophages home to the cancer site and support cancer cells angiogenesis.

Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner.

2010 Izhak, L., Wildbaum, G., Weinberg, U., Shaked, Y., Alami, J., Dumont, D., Friedman, B., Stein, A. & Karin, N. J Immunol 184, 1092-1101 (2010).
This manuscript gets into the mechanistic basis of the role of CCL2 in cancer and into a novel regulatory mechanism by which autoantibodies to CCL2 regulates the disease.

Antigen-specific CD25- Foxp3- IFN-gamma(high) CD4+ T cells restrain the development of experimental allergic encephalomyelitis by suppressing Th17.

2010 Wildbaum, G., Zohar, Y. & Karin, N. Am J Pathol 176, 2764-2775 (2010).
The manuscript defines a novel chemokine that regulates the biological functions of effector TH17 CD4+ of inflammatory autoimmune diseases.

A fusion protein encoding the second extracellular domain of CCR5 arrests chemokine-induced cosignaling and effectively suppresses ongoing experimental autoimmune encephalomyelitis.

2010 Sapir, Y., Vitenshtein, A., Barsheshet, Y., Zohar, Y., Wildbaum, G. & Karin, N. J Immunol 185, 2589-2599 (2010).
This manuscript investigates the role of CCR5 ligands in autoimmunity.

A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2.

2009 Izhak, L., Wildbaum, G., Zohar, Y., Anunu, R., Klapper, L., Elkeles, A., Seagal, J., Yefenof, E., Ayalon-Soffer, M. & Karin, N. J Immunol 183, 732-739 (2009).
This is the first manuscript showing the role of CCL2 and its role in the regulation of a cancer disease.

Selective Autoantibody Production against CCL3 Is Associated with Human Type 1 Diabetes Mellitus and Serves As a Novel Biomarker for Its Diagnosis.

2009 Shehadeh, N., Pollack, S., Wildbaum, G., Zohar, Y., Shafat, I., Makhoul, R., Daod, E., Hakim, F., Perlman, R. & Karin, N. J Immunol 182, 8104-8109 (2009).
This manuscript explores our target discovery platform in human diabetes.

CXCL12 (SDF-1{alpha}) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells.

2008 Meiron, M., Zohar, Y., Anunu, R., Wildbaum, G. & Karin, N. J Exp Med 205, 2643-2655 (2008).
This is the very first manuscript that defined anti-inflammatory chemokines that direct the polarization of regulatory T cells.

Coadministration of plasmid DNA constructs encoding an encephalitogenic determinant and IL-10 elicits regulatory T cell-mediated protective immunity in the central nervous system.

2006 Schif-Zuck, S., Wildbaum, G. & Karin, N. J Immunol 177, 8241-8247 (2006).
This manuscript uses a novel technique to select in vivo IL-10high T-regs.

Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity.

2003 Wildbaum, G., Nahir, M. & Karin, N. Immunity 19, 679-688 (2003).
Base on this manuscript we have developed a target discovery platform which we are now extending to discover novel targets for therapy.

Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading.

2002 Wildbaum, G., Netzer, N. & Karin, N. J Clin Invest 110, 701-710. (2002).
This is the very first manuscript that defines the role of IL-10high regulatory T cells in inflammatory autoimmunity within the central nervous system

Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis.

2002 Wildbaum, G., Netzer, N. & Karin, N. J Immunol 168, 5885-5892 (2002).
This manuscript shows for the first time that a chemokine (CXCL10) may drive the polarization of inflammatory T cells in a model of Multiple Sclerosis.

Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis.

2002 Salomon, I., Netzer, N., Wildbaum, G., Schif-Zuck, S., Maor, G. & Karin, N. J Immunol 169, 2685-2693 (2002).
This manuscript shows the role of CXCL10 in the pathogenesis of rheumatoid arthritis.

C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis.

2000 Youssef, S., Maor, G., Wildbaum, G., Grabie, N., Gour-Lavie, A. & Karin, N. J Clin Invest 106, 361-371 (2000).
This manuscript uses the DNA vaccination technology to explore the role of chemokines in autoimmunity.

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1992 Yednock, T.A., Cannon, C., Fritz, L.C., Sanchez-Madrid, F., Steinman, L. & Karin, N. Nature 356, 63-66. (1992).
This Nature manuscript led to the development of the leading drug to Muliple Sclerosis.